“Patients receiving chemotherapy should not overlook the risk of ‘thromboembolism'”

Facebook
Twitter
LinkedIn
Pinterest
Pocket
WhatsApp

Ajou University Hospital announced on the 21st that a research team from the Department of Oncology and Hematology announced the results of a study on the occurrence of thromboembolism in cancer patients who received chemotherapy.

A research team led by Professor Miseon Ahn, Jinhyeok Choi, and Taehwan Kim of the Department of Oncology and Hematology at Ajou University Hospital studied 257 patients with locally advanced head and neck cancer who underwent simultaneous chemotherapy with cisplatin for the past 15 years and 275 patients who received adjuvant chemotherapy after surgery for non-small cell lung cancer. In this study, the frequency and risk factors for thromboembolism were analyzed.

As a result of the study, thromboembolism occurred in 5 patients with head and neck cancer (1.9%), and the Khorana score was the only significant correlation with the predictor of thromboembolism. The Korana score is calculated from blood counts such as body mass index (BMI) and white blood cell count among various clinical findings.

In NSCLC, 9 patients (3.3%) developed thromboembolism, and 7 of them had pulmonary embolism. .

A thrombus refers to a phenomenon in which a clot of blood blocks a blood vessel. The reason blood clots are scary is that thromboembolism, or thromboembolism, can lead to death by blocking the blood vessels of the brain, lungs, or heart that can be fatal while floating in the blood vessels.

This study is the first to analyze how many thromboembolism occurs and what are the risk factors in the case of head and neck cancer and non-small cell lung cancer that has undergone surgery. seems to be

Read Also  Pujols's return to the old nest is ale from the old and new commanders "There is still power" "Great" | Full-Count

Professor Ahn Mi-sun said, “The occurrence of thromboembolism, which can be fatal, has been confirmed in both diseases, and a high corona score or smoking is identified as a risk factor, so it is necessary to explain thromboembolism before treatment of the patient.”

This study was published in SCI(E)-level academic journal, the Journal of Internal Medicine, and Scientific Reports, a sister journal of Nature, in May, respectively.

Jeon Hye-young, reporter for Money Today Broadcasting MTN

Facebook
Twitter
LinkedIn
Pinterest
Pocket
WhatsApp

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Recent News

Editor's Pick